Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao
Institutions: Shanghai Jiao Tong University, Ruijin Hospital, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Second Affiliated Hospital of Zhejiang University, Zhejiang University, Ningbo University, Zhengzhou University, Henan Cancer Hospital, Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center, Zhujiang Hospital, Southern Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, First Affiliated Hospital of Zhengzhou University, Tongji University, Peking University Third Hospital, Shandong University, Qilu Hospital of Shandong University, Sichuan University, West China Hospital of Sichuan University, First Affiliated Hospital of Nanchang University, Tongji Hospital, Huazhong University of Science and Technology, Wuhan Union Hospital, First Affiliated Hospital of Soochow University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417008334
Cites:
Cited by:
Related to: